首页 | 本学科首页   官方微博 | 高级检索  
检索        

HER-2阳性乳腺癌中肿瘤浸润淋巴细胞与雄激素受体的相关性研究
引用本文:刘方,曹璐,许聪,向国敏,牛昀.HER-2阳性乳腺癌中肿瘤浸润淋巴细胞与雄激素受体的相关性研究[J].中国肿瘤临床,2019,46(8):389-393.
作者姓名:刘方  曹璐  许聪  向国敏  牛昀
作者单位:天津医科大学肿瘤医院乳腺病理研究室,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室(天津市 300060)
基金项目:天津市应用基础与前沿技术研究计划基金项目15JCYBJC27800
摘    要:目的:探讨人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)阳性乳腺癌中肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes,TILs)浸润水平与雄激素受体(androgen receptor,AR)表达的关系。方法:收集2018年3月至2018年11月天津医科大学肿瘤医院收治的448例HER-2阳性乳腺癌患者的临床资料。病理评估TILs浸润水平,免疫组织化学方法检测AR表达情况,分析TILs浸润水平和AR表达与临床病理学参数的关系以及TILs和AR的相关性。结果:448例HER-2阳性乳腺癌患者中TILs无浸润或低浸润的患者占38.2%(171/448)、中等浸润者占42.2%(189/448)、高浸润者占19.6%(88/448),AR阳性率为62.7%(281/448)。Spearman等级相关分析显示TILs浸润水平与AR表达呈负相关(r=-0.140,P=0.003)。在雌激素受体(estrogenreceptor,ER)阳性乳腺癌中,TILs浸润水平和AR表达密切相关(P=0.009)。结论:HER-2阳性乳腺中TILs浸润水平和AR表达呈负相关,提示HER-2阳性乳腺癌患者可根据TILs的不同浸润水平与AR的表达行精准治疗。

关 键 词:乳腺癌  人表皮生长因子受体-2  肿瘤浸润淋巴细胞  雄激素受体
收稿时间:2019-03-07

Correlation between tumor-infiltrating lymphocytes and the androgen receptor in HER-2-positive breast cancer
Fang Liu,Lu Cao,Cong Xu,Guomin Xiang,Yun Niu.Correlation between tumor-infiltrating lymphocytes and the androgen receptor in HER-2-positive breast cancer[J].Chinese Journal of Clinical Oncology,2019,46(8):389-393.
Authors:Fang Liu  Lu Cao  Cong Xu  Guomin Xiang  Yun Niu
Institution:Department of Breast Cancer Pathology and Research Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China
Abstract:  Objective  To investigate the relationship between tumor-infiltrating lymphocytes (TILs) and the androgen receptor (AR) in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer.  Methods  Specimens of 448 patients with HER-2-positive breast cancer from the Tianjin Medical University Cancer Hospital between March 2018 and November 2018 were collected. TILs were pathologically evaluated. AR expression was immunohistochemically analyzed. The relationships among TILs, the AR, and clinicopathological parameters were determined.  Results  There were 38.2% (171/448) patients with TILs non/low-infiltrated, 42.2% (189/448) with moderately infiltrated, and 19.6% (88/448) with high infiltration. AR was positive in 62.7%(281/448) of the patients. Spearman correlation analysis showed that TILs and the AR were negatively related (r=-0.140, P=0.003). TILs were significantly associated with the AR in estrogen receptor positive breast cancer (P=0.009).  Conclusions  TILs and the AR were negatively related in HER-2-positive breast cancer, indicating that HER-2-positive breast cancer can be treated according to the different infiltration levels of TILs and AR expression. 
Keywords:breast cancer  human epidermal growth factor receptor 2 (HER-2)  tumor-infiltrating lymphocytes  androgen receptor
本文献已被 维普 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号